Business Wire

CA-THEOREM-LLC

4.8.2021 12:02:09 CEST | Business Wire | Press release

Share
Theorem, LLC Launches Theorem Orbital, a New Division Providing an End-to-End Suite of Space and Satellite Logistics Services

Theorem, LLC , an innovation and engineering firm that builds custom enterprise software for the world’s most admired brands, today launched Theorem Orbital , a new division focused on end-to-end space logistics and enablement for the Global 2000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005393/en/

“Today, only 100 of the Global 2000 have active space programs, but that number will increase tenfold over the next decade,” said Brady Brim-DeForest, CEO of Theorem. “The space industry can seem intimidating and hard to navigate — we are here to help make navigating it easy and transparent.”

While recent space-related startups have focused primarily on delivering launch-side capability, other aspects of the space industry are experiencing significant growth , and game-changing opportunities have become within reach for even those who have made minimal investments to date. These include bespoke satellite programs focused on activities like earth observation, remote sensing, and satellite-enabled communications and connectivity.

Theorem Orbital will leverage its direct relationships with space launch providers, prime contractors and suppliers, universities, and NGOs, allowing for a wide range of services tailored to clients expanding their existing footprint, or building a space strategy from the ground up. Theorem Orbital’s preferred providers for launch services and space-based data today include Rocket Lab , Virgin Orbit , Firefly Aerospace , and Satellogic .

“Our partnership with Theorem will help further our mission of democratizing access to Earth Observation data,” said Thomas VanMatre, Satellogic’s Vice President of Global Business Development. “The combination of Theorem’s world-class software innovation and engineering capabilities and Satellogic’s unit cost advantage will unlock a multitude of use cases for the commercial market.”

As part of its commitment to opening up access to space as a strategic resource for the enterprise, mid-market, and academic markets, Theorem is also announcing a strategic investment into bluShift Aerospace , the Brunswick, Maine based maker of the Starless Rogue launch platform that is designed to enable a low barrier to entry for a diverse collection of payloads into the suborbital space ecosystem.

"bluShift’s approach to developing cost-effective and sustainable next-generation rocket technology will open up space to new markets," said Sascha Deri, CEO of bluShift Aerospace. "We feel that our mission and philosophy are well aligned with Theorem Orbital's commitment to lowering the barrier to entry for companies beginning to leverage space-based infrastructure in their mid and long-term strategic plans. We're pleased to welcome them as an investor, and excited to collaborate on uncovering opportunities to accelerate the adoption of bluShift capabilities within the enterprise market."

At launch, Theorem Orbital’s initial suite of services will include:

  • Satellite Data & Connectivity Strategy and Planning - Strategy services designed to enable clients to leverage data and connectivity generated by existing satellite infrastructure, as well as planning for proprietary constellations.
  • Advanced-Data Analysis - Real-time satellite imagery and remote communication networks are shifting how construction, agriculture, real estate, retail, travel, and mining industries run their daily operations, quarterly planning, risk management, insurance negotiations, and other major drivers of their bottom line. Data providers like Satellogic are opening new use cases daily — Theorem Orbital can help clients make the most of this rapidly evolving field.
  • Software Platform Development - Theorem Orbital designs and builds advanced proprietary software platforms that bring together advanced space-based data sources with existing internal enterprise data and systems.
  • Hardware Development - Theorem Orbital can assist clients in utilizing Satellogic’s unique hosted payload program to rapidly prototype and fly proprietary and commercial off-the-shelf sensors to meet client requirements.
  • Internet-in-Space - Theorem Orbital can assist clients in establishing their own IoT communications network in space including the design and launch of bespoke constellations through preferred launch providers.
  • Launch - Theorem Orbital partners with preferred providers — including Virgin Orbit, Rocket Lab, SpaceX, and more — in order to enable the launch of custom payloads into low-earth and near-earth orbit.

“The cost of putting satellites into space has been dramatically reduced due to the innovations from launch providers such as SpaceX, Rocket Lab, and others,” said Nicolas Spurlock, Director of Corporate Strategy at Theorem. “Now is the time for large enterprises to invest in building their own space-based infrastructure and gain an advantage in the new Space 2.0 era.”

Start charting your course to space by learning more at theoremorbital.com .

About Theorem

Theorem, LLC is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, we make great user experiences accessible to the enterprise. Founded in 2007, Theorem’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how we enable ambitious leaders to build better software, visit www.theorem.co or follow @TheoremCo .

Link:

ClickThru

Social Media:

https://www.facebook.com/theoremteam

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye